NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Car-t trial: See arm results below. Arm 5 supposedly did the best, but the two longest living patients did not have GBM (they had idh1 mutation). So did one of the two longest living in arm two. The eyeball test says arm 2 and arm 5 were about the same. Again it looks like the patient whose study you analyzed, is patient 109 from arm two. If you take out the idh1 mutation patients from this trial (not GBM), no one lived four years, and just one patient out of 65 lived over 36 months. They wanted to show their elaborate administration and new manufacturing test in arm five was better, so they did some mumbo jumbo combining of arm one and two so arm two was not directly compared to arm five for survival purposes, but again, you can see it clear as day in the chart below.

https://www.nature.com/articles/s41591-024-02875-1.pdf

Note: I think your second question was answered by antihama.